Patents by Inventor Rosanne Bonjouklian

Rosanne Bonjouklian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase inhibitors
    Patent number: 7863310
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Timothy Alan Shepherd
  • KINASE INHIBITORS
    Publication number: 20090318443
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: July 27, 2009
    Publication date: December 24, 2009
    Inventors: Rosanne Bonjouklian, Chafiq Hamdouchi Hamdouchi, Chuan Shih, Alfonso De Dios, Miriam Filadelfa Del Prado, Carlos Jaramillo Aguado, Pramila Kotiyan, Mary Margaret Mader, Sheila Pleite Selgas, Concepcion Sanchez-Martinez
  • Kinase inhibitors
    Patent number: 7582652
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Chafiq Hamdouchi, Chuan Shih, Alfonso De Dios, Miriam Filadelfa del Prado, Carlos Jaramillo Aguado, Pramila Kotiyan, Mary Margaret Mader, Sheila Pleite Selgas, Concepcion Sanchez-Martinez
  • KINASE INHIBITORS
    Publication number: 20090036445
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: January 25, 2005
    Publication date: February 5, 2009
    Inventors: Rosanne Bonjouklian, Chafiq Hamdouchi, Chuan Shih, Alfonso De Dios, Miriam Filadelfa del Prado, Carlos Jaramillo Aguado, Pramila Kotiyan, Mary Margaret Mader, Sheila Pleite Selgas, Concepcion Sanchez-Martinez
  • Kinase Inhibitors
    Publication number: 20080227839
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: January 21, 2005
    Publication date: September 18, 2008
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Carlos Montero Salgado, Timothy Alan Shepherd
  • Pyrazolopyridine derivatives as pharmaceutical agents
    Patent number: 7365066
    Abstract: Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Rosanne Bonjouklian, Junkai Liao, William Thomas McMillen, Brandon Lee Parkhurst, Jason Scott Sawyer, Jonathan Michael Yingling, Jeremy Schulenburg York
  • Benzimidazoles and benzothiazoles as inhibitors of map kinase
    Patent number: 7320995
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose Eugenio De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi Hamdouchi, Tiecho Li, Beatriz Lopez De Uralde Garmendia, Michal Vieth, Jeremy Schulenberg York, Robert Dean Dally, Miriam Filadelfa Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Maria Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Alan Shepherd, James Howard Wikel
  • Compounds and methods for inhibiting MRP1
    Patent number: 7037921
    Abstract: The present invention relates to a compound of Formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Louis Nickolaus Jungheim, Kenneth Jeff Thrasher
  • Benzimidazoles and benzothiazoles as inhibitors of map kinase
    Publication number: 20050272791
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis.
    Type: Application
    Filed: July 31, 2003
    Publication date: December 8, 2005
    Applicant: Eil Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi, Tiecho Li, Beatriz De Uralde Garmendia, Michal Vieth, Jeremy York, Robert Dally, Miriam Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Shepherd, James Wikel
  • Novel pyrazolopyridine derivatives as pharmaceutical agents
    Publication number: 20050222197
    Abstract: Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
    Type: Application
    Filed: September 16, 2003
    Publication date: October 6, 2005
    Inventors: Douglas Beight, Rosanne Bonjouklian, Junkai Liao, William McMillen, Brandon Parkhurst, Jason Sawyer, Jonathan Yingling, Jeremy York
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Compounds and methods for inhibiting mrp1
    Publication number: 20040097507
    Abstract: The present invention relates to a compound of Formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: September 25, 2003
    Publication date: May 20, 2004
    Inventors: Rosanne Bonjouklian, Louis Nikolaus Jungheim, Kenneth Jeff Thrasher
  • Compounds and methods for inhibiting MRP1
    Publication number: 20040077675
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 22, 2004
    Inventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Screenivasara Vepachedu, Yongping Xie
  • Methods and compounds for inhibiting MRP1
    Patent number: 6686376
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: February 3, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeremy Schulenburg York
  • Compounds and method for inhibiting MRP1
    Patent number: 6670373
    Abstract: The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: December 30, 2003
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Sreenivasarao Vepachedu, Yongping Xie
  • Methods and compounds for inhibiting mrp1
    Publication number: 20030100576
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: May 21, 2002
    Publication date: May 29, 2003
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst
  • Inhibition of phosphatidylinositol 3-kinase with 17 .beta.-hydroxywortmannin and analogs thereof
    Patent number: 5504103
    Abstract: 17.beta.-hydroxywortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: April 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey A. Dodge, Chris J. Vlahos
  • Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
    Patent number: 5378725
    Abstract: Wortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.
    Type: Grant
    Filed: July 19, 1993
    Date of Patent: January 3, 1995
    Assignees: The Arizona Board of Regents, Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Chris J. Vlahos, Garth Powis
  • Strain of streptomyces for producing avermectins and processes therewith
    Patent number: 5292647
    Abstract: A new microorganism, Streptomyces avermitilis subspecies niger NRRL 21005, and processes using the microorganism for producing known avermectins are provided.
    Type: Grant
    Filed: November 30, 1992
    Date of Patent: March 8, 1994
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Otis W. Godfrey, Tim A. Smitka, Raymond C. Yao
  • Derivatives of erythromycylamine
    Patent number: 5110800
    Abstract: Three new groups of 9-N-substituted derivatives of erythromycylamine with superior oral activity against Gram-positive pathogens, new processes for preparing derivatives of erythromycylamine and aliphatic aldehydes by controlling the pH of the reaction and by catalytic hydrogenation, and pharmaceutical compositions and methods using the new compounds are provided.
    Type: Grant
    Filed: August 18, 1989
    Date of Patent: May 5, 1992
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Manuel Debono, Herbert A. Kirst, Julie A. Wind